Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML

TOKYO and BASKING RIDGE, N.J., April 4, 2019 -- (Healthcare Sales & Marketing Network) -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the N... Biopharmaceuticals, Oncology, FDA Daiichi Sankyo, quizartinib, acute myeloid leukemia, FLT3 inhibitor
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news